Brought to you by 
Gilead to market Virco's HIV tests
16 Apr 2001
Executive Summary
Gilead (anti-infectives) will market Virco's (pharmacogenomic tests) HIV monitoring tests and services, initially in the US, however the companies expect Europe and Australia to be added in the next few months.
Deal Industry
- In Vitro Diagnostics
- Laboratory Testing Services
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead to market Virco's HIV tests
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice